Your session is about to expire
← Back to Search
Other
MTL-CEBPA + Sorafenib for Liver Cancer (OUTREACH2 Trial)
Phase 2
Waitlist Available
Research Sponsored by Mina Alpha Limited
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Eastern Cooperative Oncology Group performance status of 0 or 1
Naïve to tyrosine kinase inhibitors, including sorafenib, regorafenib, cabozantinib, and lenvatinib
Must not have
Participants with sepsis, ineffective biliary drainage with or without cholangitis, obstructive jaundice, or encephalopathy at screening visit or within the last 2 weeks prior to study treatment initiation
Participants with no prior therapy who are eligible for first-line treatment with atezolizumab in combination with bevacizumab
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from first cycle of treatment to end of study approximately one year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing an experimental treatment (MTL-CEBPA) in combination with a standard of care treatment (sorafenib) in patients with advanced liver cancer (hepatocellular carcinoma) as a result of hepatitis B and/or C infection.
Who is the study for?
This trial is for adults with advanced liver cancer due to hepatitis B/C, who have a life expectancy of over 3 months and are not suitable for surgery or liver transplant. They should be new to tyrosine kinase inhibitors like sorafenib and must have normal organ function tests. Pregnant women, those with severe liver impairment (Child-Pugh B/C), recent serious cardiovascular issues, other active cancers, or known allergies to the drugs tested cannot participate.
What is being tested?
The study compares two approaches: one group receives MTL-CEBPA via IV every three weeks plus oral Sorafenib starting Day 8; the other gets only Sorafenib from Day 1. The goal is to see if adding MTL-CEBPA improves outcomes in hepatocellular carcinoma patients who've had hepatitis B/C.
What are the potential side effects?
Potential side effects include reactions at the infusion site for MTL-CEBPA, as well as common drug-related risks such as fatigue, digestive problems, skin reactions and high blood pressure from Sorafenib. Previous studies suggest that combining these treatments has an acceptable safety profile.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am fully active or restricted in physically strenuous activity but can do light work.
Select...
I have not taken any tyrosine kinase inhibitor medications.
Select...
I have advanced liver cancer with cirrhosis, and a history of hepatitis B or C.
Select...
I am not a candidate for liver transplantation.
Select...
I can swallow and keep down pills.
Select...
My liver cancer worsened after treatment with atezolizumab and bevacizumab.
Select...
I am using reliable birth control methods.
Select...
My liver function is good.
Select...
My liver tumor cannot be surgically removed and hasn't responded to targeted treatments.
Select...
My liver cancer is at an advanced stage.
Select...
My kidneys are functioning well enough to filter waste.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had sepsis, issues with bile drainage, jaundice, or brain function problems recently.
Select...
I am eligible for my first cancer treatment with atezolizumab and bevacizumab.
Select...
I have had an organ transplant.
Select...
My liver cancer is of a specific type (fibrolamellar or mixed).
Select...
I have liver-related brain issues not improved with treatment in the last 6 months.
Select...
I have HIV with low CD4+ T-cell counts or a history of severe infections.
Select...
My cancer has spread to my brain or spinal cord.
Select...
I have another cancer that has been active or treated in the last 5 years.
Select...
I have an immune system disorder or I am on long-term steroids.
Select...
I have never had hepatitis B or C.
Select...
My liver disease is moderately to severely advanced.
Select...
I have had bleeding or a tear in my stomach or intestines.
Select...
I have had spontaneous bacterial peritonitis, renal failure, or an allergic reaction recently.
Select...
I have a significant buildup of fluid in my abdomen.
Select...
I am not allergic to MTL-CEBPA or sorafenib or their ingredients.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ from first cycle of treatment to end of study approximately one year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from first cycle of treatment to end of study approximately one year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Progression free survival (PFS)
Secondary study objectives
Adverse events
Health-related quality of life (HRQoL) questionnaires
Overall survival (OS)
Side effects data
From 2022 Phase 3 trial • 87 Patients • NCT0206618173%
Fatigue
71%
Palmar-plantar erythrodysesthesia syndrome
63%
Hypertension
61%
Papulopustular rash
55%
Diarrhea
51%
Nausea
39%
Myalgia
37%
Alopecia
35%
Arthralgia
33%
Abdominal pain
31%
Anorexia
27%
Vomiting
22%
Mucositis oral
22%
Constipation
18%
Anemia
18%
Alanine aminotransferase increased
16%
Platelet count decreased
14%
Pruritus
14%
Hyperglycemia
14%
Rash maculo-papular
14%
Skin and subcutaneous tissue disorders - Other, specify
12%
Aspartate aminotransferase increased
12%
Rash acneiform
12%
Peripheral sensory neuropathy
10%
Investigations - Other, specify
10%
Dry skin
10%
Neutrophil count decreased
10%
Blood bilirubin increased
8%
Back pain
8%
Headache
8%
Nervous system disorders - Other, specify
8%
Pain in extremity
6%
General disorders and administration site conditions - Other, specify
6%
Skin infection
6%
White blood cell decreased
6%
Hypercalcemia
6%
Hypokalemia
6%
Musculoskeletal and connective tissue disorder - Other, specify
6%
Dizziness
6%
Respiratory, thoracic and mediastinal disorders - Other, specify
6%
Eye disorders - Other, specify
6%
Hyperkalemia
6%
Pain
6%
Alkaline phosphatase increased
6%
Hypocalcemia
6%
Cough
4%
Flushing
4%
Tinnitus
4%
Dental caries
4%
Gastrointestinal disorders - Other, specify
4%
Hemoglobin increased
4%
Weight loss
4%
Metabolism and nutrition disorders - Other, specify
4%
Dysgeusia
4%
Anxiety
4%
Irregular menstruation
4%
Menorrhagia
4%
Sore throat
4%
Lymphocyte count decreased
4%
Hyperuricemia
4%
Non-cardiac chest pain
4%
Infections and infestations - Other, specify
4%
Hypernatremia
4%
Hypoglycemia
4%
Scalp pain
4%
Dry mouth
2%
Blurred vision
2%
Hypothyroidism
2%
Urticaria
2%
Hemorrhoids
2%
Acute kidney injury
2%
Palpitations
2%
Leukocytosis
2%
Myocardial infarction
2%
Vertigo
2%
Anal hemorrhage
2%
Dysphagia
2%
Esophageal pain
2%
Periodontal disease
2%
Fever
2%
Sinusitis
2%
Urinary tract infection
2%
Bruising
2%
Dermatitis radiation
2%
Cholesterol high
2%
Creatinine increased
2%
Neck pain
2%
Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify
2%
Concentration impairment
2%
Memory impairment
2%
Spasticity
2%
Depression
2%
Insomnia
2%
Allergic rhinitis
2%
Productive cough
2%
Sleep apnea
2%
Pregnancy, puerperium and perinatal conditions - Other, specify
2%
Dry eye
2%
Lymphedema
2%
Chest pain - cardiac
2%
Heart failure
2%
Gastric perforation
2%
Hypertriglyceridemia
2%
Dyspnea
2%
Cardiac disorders - Other, specify
2%
Gastroesophageal reflux disease
2%
Oral dysesthesia
2%
Chills
2%
Hypophosphatemia
2%
Chest wall pain
2%
Psychiatric disorders - Other, specify
2%
Hematuria
2%
Urinary tract obstruction
2%
Dysmenorrhea
2%
Skin hypopigmentation
2%
Unintended pregnancy
2%
Flu like symptoms
2%
Nail infection
2%
Pancreatitis
2%
Blood and lymphatic system disorders - Other, specify
2%
Oral pain
2%
Fall
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm I (Sorafenib Tosylate)
Arm II (Placebo)
Crossover Group
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: MTL-CEBPA in combination with sorafenibExperimental Treatment2 Interventions
Intravenous infusion of MTL-CEBPA 130mg/m2 given once every 3 weeks. Oral sorafenib 400mg twice a day will commence C1D8.
Group II: Sorafenib aloneActive Control1 Intervention
Oral sorafenib 400mg twice a day commencing Day1
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Sorafenib
2014
Completed Phase 3
~1670
Find a Location
Who is running the clinical trial?
Mina Alpha LimitedLead Sponsor
2 Previous Clinical Trials
183 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- I am fully active or restricted in physically strenuous activity but can do light work.I have not taken any tyrosine kinase inhibitor medications.I have advanced liver cancer with cirrhosis, and a history of hepatitis B or C.I am not a candidate for liver transplantation.I can swallow and keep down pills.I have not had sepsis, issues with bile drainage, jaundice, or brain function problems recently.I am eligible for my first cancer treatment with atezolizumab and bevacizumab.My side effects from previous treatments are mild or gone, except for hair loss or hormone issues which are under control.I haven't had serious heart problems in the last year.I have had an organ transplant.I have not had major surgery in the last 30 days.My liver cancer is of a specific type (fibrolamellar or mixed).I have liver-related brain issues not improved with treatment in the last 6 months.I have HIV with low CD4+ T-cell counts or a history of severe infections.I have not received a live vaccine in the last 30 days.My liver cancer worsened after treatment with atezolizumab and bevacizumab.I am using reliable birth control methods.My cancer has spread to my brain or spinal cord.I have another cancer that has been active or treated in the last 5 years.I have an immune system disorder or I am on long-term steroids.I haven't had significant bleeding episodes in the last 3 months.I am a man and will use effective birth control if my partner can have children.I have never had hepatitis B or C.My liver disease is moderately to severely advanced.I have had bleeding or a tear in my stomach or intestines.I am 18 years old or older.My liver function is good.My liver tumor cannot be surgically removed and hasn't responded to targeted treatments.My liver cancer is at an advanced stage.I have had spontaneous bacterial peritonitis, renal failure, or an allergic reaction recently.My kidneys are functioning well enough to filter waste.I have a significant buildup of fluid in my abdomen.I am not allergic to MTL-CEBPA or sorafenib or their ingredients.
Research Study Groups:
This trial has the following groups:- Group 1: MTL-CEBPA in combination with sorafenib
- Group 2: Sorafenib alone
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger